Change-point survival models for relative treatment effect extrapolation
This method helps predict how well a treatment works over the long term by identifying points in time when the treatment's effect changes, such as when benefits start, fade, or when outcomes between treatment groups begin to look more similar. It uses real data patterns to make more believable long-term predictions.
At a glance
Use when
Modeling long-term survival outcomes where treatment effects are expected to change over time (e.g., delayed onset, diminishing benefit, or convergence of hazards); when standard parametric models produce implausible extrapolations.
Avoid when
When follow-up data are too short to identify change-points; when there is no clinical or empirical basis for expecting a change in treatment effect over time.
Inputs
Time-to-event data from clinical trials, including survival curves and hazard ratios over time; prior distributions for model parameters in Bayesian implementation.
Outputs
Estimated change-point(s) in treatment effect, extrapolated survival functions, hazard ratios over time with uncertainty intervals, model fit statistics.
How it works
Change-point survival models estimate shifts in relative treatment effects over time, such as treatment delay, loss of effect, or converging hazards, by introducing one or more change-points in the hazard ratio. Implemented within a Bayesian framework using standard statistical software, these models allow flexible modeling of observed survival data and propagate uncertainty in all parameters, including the location of the change-point. The method was evaluated via simulation and applied to real datasets from prior HTAs, showing improved fit and more clinically plausible extrapolations compared to standard and flexible parametric models.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Patient and Social Aspects
- Assumptions
- The relative treatment effect changes at one or more identifiable time points (change-points); the form of the change (e.g., step change, linear transition) is specified; proportional hazards hold between change-points.
- Strengths
- Allows clinically plausible modeling of non-proportional hazards, such as delayed or waning treatment effects,Quantifies uncertainty in change-point location and treatment effect changes,Provides better fit and more believable extrapolations than standard models when effect changes are present,Can support or challenge modeling assumptions made on visual inspection alone
- Limitations
- Requires sufficient follow-up data to detect change-points reliably,Model complexity increases with number of change-points, risking overfitting,Results may be sensitive to prior specifications in Bayesian framework,Limited ability to extrapolate beyond the last observed event if no clear pattern is present
- Also known as
- change-point models, Bayesian change-point survival models, relative treatment effect change-point models
Questions this answers
- › When does the treatment effect begin to manifest over time?
- › Does the treatment benefit diminish or disappear after a certain period?
- › Do hazard ratios converge between treatment groups in the long term?
- › How can uncertainty in the timing of treatment effect changes be quantified?
- › Are observed changes in relative treatment effects statistically supported?
- › How do change-point models compare to standard parametric models in extrapolating survival outcomes?
References & sources
Similar by meaning
- Survival extrapolation validation-based case study (Bullement et al.)
- Survival extrapolation incorporating general-population mortality using excess-hazard and cure models (Sweeting et al. tutorial)
- survextrap
- Fractional polynomial network meta-analysis of survival data
- NICE DSU Technical Support Document 14
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.